company background image
XLO

Xilio Therapeutics NasdaqGS:XLO Stock Report

Last Price

US$3.62

Market Cap

US$99.2m

7D

-8.8%

1Y

-65.3%

Updated

06 Feb, 2023

Data

Company Financials +

Xilio Therapeutics, Inc.

NasdaqGS:XLO Stock Report

Mkt Cap: US$99.2m

XLO Stock Overview

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients.

XLO fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

My Notes

New

Notes are coming soon

Xilio Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Xilio Therapeutics
Historical stock prices
Current Share PriceUS$3.62
52 Week HighUS$14.86
52 Week LowUS$1.95
Beta0
1 Month Change33.21%
3 Month Change56.49%
1 Year Change-65.33%
3 Year Changen/a
5 Year Changen/a
Change since IPO-77.38%

Recent News & Updates

We Think Xilio Therapeutics (NASDAQ:XLO) Needs To Drive Business Growth Carefully

Aug 11
We Think Xilio Therapeutics (NASDAQ:XLO) Needs To Drive Business Growth Carefully

Recent updates

We Think Xilio Therapeutics (NASDAQ:XLO) Needs To Drive Business Growth Carefully

Aug 11
We Think Xilio Therapeutics (NASDAQ:XLO) Needs To Drive Business Growth Carefully

Shareholder Returns

XLOUS BiotechsUS Market
7D-8.8%-0.8%1.7%
1Y-65.3%4.3%-9.6%

Return vs Industry: XLO underperformed the US Biotechs industry which returned 4.3% over the past year.

Return vs Market: XLO underperformed the US Market which returned -9.6% over the past year.

Price Volatility

Is XLO's price volatile compared to industry and market?
XLO volatility
XLO Average Weekly Movement14.9%
Biotechs Industry Average Movement12.1%
Market Average Movement6.7%
10% most volatile stocks in US Market17.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: XLO is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.

Volatility Over Time: XLO's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201678Rene Russohttps://www.xiliotx.com

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases.

Xilio Therapeutics, Inc. Fundamentals Summary

How do Xilio Therapeutics's earnings and revenue compare to its market cap?
XLO fundamental statistics
Market CapUS$99.21m
Earnings (TTM)-US$85.46m
Revenue (TTM)n/a

0.0x

P/S Ratio

-1.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
XLO income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$85.46m
Earnings-US$85.46m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-3.12
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio7.7%

How did XLO perform over the long term?

See historical performance and comparison